[Expert consensus on the management of B-cell lymphoma-related cardiovascular diseases with Bruton tyrosine kinase inhibitors (2023)].
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2023 May 14;44(5):359-365. doi: 10.3760/cma.j.issn.0253-2727.2023.05.002.
Abstract
摘要
相似文献
1
[Expert consensus on the management of B-cell lymphoma-related cardiovascular diseases with Bruton tyrosine kinase inhibitors (2023)].
Zhonghua Xue Ye Xue Za Zhi. 2023 May 14;44(5):359-365. doi: 10.3760/cma.j.issn.0253-2727.2023.05.002.
2
Bruton Tyrosine Kinase Inhibitor in 2 Patients With Vitreoretinal Lymphoma.
JAMA Ophthalmol. 2023 Nov 1;141(11):1085-1088. doi: 10.1001/jamaophthalmol.2023.4509.
3
Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.布鲁顿酪氨酸激酶抑制剂在 B 细胞恶性肿瘤中的应用及其特点。
Target Oncol. 2022 Jan;17(1):69-84. doi: 10.1007/s11523-021-00857-8. Epub 2021 Dec 14.
4
Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.布鲁顿酪氨酸激酶抑制剂治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的代谢和毒理学考虑。
Expert Opin Drug Metab Toxicol. 2024 Apr;20(4):207-224. doi: 10.1080/17425255.2024.2334322. Epub 2024 Mar 25.
5
Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.泊鲁替尼：首个用于治疗成人复发/难治性套细胞淋巴瘤的非共价酪氨酸激酶抑制剂。
Curr Med Chem. 2024;31(30):4757-4762. doi: 10.2174/0109298673251030231004052822.
6
Transformed mantle cell lymphoma with additional triple-hit genotypes can be resistant to a Bruton tyrosine kinase inhibitor.具有额外三打击基因型的转化型套细胞淋巴瘤可能对布鲁顿酪氨酸激酶抑制剂耐药。
Blood. 2024 May 16;143(20):2106. doi: 10.1182/blood.2024023818.
7
New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?用于治疗套细胞淋巴瘤的新型及新兴布鲁顿酪氨酸激酶抑制剂——它们处于什么地位？
Expert Rev Hematol. 2018 Sep;11(9):749-756. doi: 10.1080/17474086.2018.1506327. Epub 2018 Aug 2.
8
Combining forces for good: chimeric antigen receptor T-cells and Bruton tyrosine kinase inhibitors in mantle cell lymphoma with central nervous system involvement.携手向善：嵌合抗原受体T细胞与布鲁顿酪氨酸激酶抑制剂在合并中枢神经系统受累的套细胞淋巴瘤中的应用
Leuk Lymphoma. 2024 May;65(5):546-547. doi: 10.1080/10428194.2024.2320833. Epub 2024 Feb 29.
9
Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd-Generation Bruton Tyrosine Kinase Inhibitor-Based Therapies. upfront 管理 blastoid 变体套细胞淋巴瘤：基于第二代/第三代 Bruton 酪氨酸激酶抑制剂治疗的病例。
Cancer Med. 2024 Oct;13(19):e70310. doi: 10.1002/cam4.70310.
10
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.ZUMA-2 与 Pirtobrutinib 在先前接受共价布鲁顿酪氨酸激酶抑制剂治疗的复发/难治性套细胞淋巴瘤患者中的匹配调整间接比较。
Adv Ther. 2024 May;41(5):1938-1952. doi: 10.1007/s12325-024-02822-z. Epub 2024 Mar 18.
本文引用的文献
1
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.奥雷巴替尼在复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中的疗效：多中心、单臂、开放标签、2 期研究。
Am J Hematol. 2023 Apr;98(4):571-579. doi: 10.1002/ajh.26826. Epub 2023 Jan 22.
2
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.泽布替尼或伊布替尼用于复发或难治性慢性淋巴细胞白血病
N Engl J Med. 2023 Jan 26;388(4):319-332. doi: 10.1056/NEJMoa2211582. Epub 2022 Dec 13.
3
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).2022年欧洲心脏病学会（ESC）与欧洲血液学协会（EHA）、欧洲治疗放射学与肿瘤学协会（ESTRO）以及国际心脏肿瘤学会（IC-OS）合作制定的心脏肿瘤学指南。
Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.
4
International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL.国际共识声明：慢性淋巴细胞白血病中布鲁顿酪氨酸激酶抑制剂的心血管风险管理。
Blood Adv. 2022 Sep 27;6(18):5516-5525. doi: 10.1182/bloodadvances.2022007938.
5
Cardiotoxicity of BTK inhibitors: ibrutinib and beyond.布鲁顿酪氨酸激酶（BTK）抑制剂的心脏毒性：依鲁替尼及其他。
Expert Rev Hematol. 2022 Apr;15(4):321-331. doi: 10.1080/17474086.2022.2067526. Epub 2022 Apr 22.
6
Management of cardiovascular complications of bruton tyrosine kinase inhibitors.布鲁顿酪氨酸激酶抑制剂心血管并发症的管理
Br J Haematol. 2022 Jan;196(1):70-78. doi: 10.1111/bjh.17788. Epub 2021 Sep 8.
7
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.阿卡替尼与伊布替尼治疗既往治疗的慢性淋巴细胞白血病：首次随机 III 期试验结果。
J Clin Oncol. 2021 Nov 1;39(31):3441-3452. doi: 10.1200/JCO.21.01210. Epub 2021 Jul 26.
8
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.阿卡拉布替尼用于对依鲁替尼不耐受的复发/难治性慢性淋巴细胞白血病患者的II期研究。
Haematologica. 2021 Sep 1;106(9):2364-2373. doi: 10.3324/haematol.2020.272500.
9
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.泊鲁替尼治疗复发或难治性 B 细胞恶性肿瘤（BRUIN）：一项 1/2 期研究。
Lancet. 2021 Mar 6;397(10277):892-901. doi: 10.1016/S0140-6736(21)00224-5.
10
Managing toxicities of Bruton tyrosine kinase inhibitors.布鲁顿酪氨酸激酶抑制剂的毒性管理。
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):336-345. doi: 10.1182/hematology.2020000118.
Zotero 插件